159 related articles for article (PubMed ID: 25978737)
1. Identification of highly reactive cysteine residues at less exposed positions in the Fab constant region for site-specific conjugation.
Shiraishi Y; Muramoto T; Nagatomo K; Shinmi D; Honma E; Masuda K; Yamasaki M
Bioconjug Chem; 2015 Jun; 26(6):1032-40. PubMed ID: 25978737
[TBL] [Abstract][Full Text] [Related]
2. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs.
Junutula JR; Bhakta S; Raab H; Ervin KE; Eigenbrot C; Vandlen R; Scheller RH; Lowman HB
J Immunol Methods; 2008 Mar; 332(1-2):41-52. PubMed ID: 18230399
[TBL] [Abstract][Full Text] [Related]
3. One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.
Shinmi D; Taguchi E; Iwano J; Yamaguchi T; Masuda K; Enokizono J; Shiraishi Y
Bioconjug Chem; 2016 May; 27(5):1324-31. PubMed ID: 27074832
[TBL] [Abstract][Full Text] [Related]
4. Attachment Site Cysteine Thiol pK
Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
[TBL] [Abstract][Full Text] [Related]
6. Site-specific conjugation of bifunctional chelator BAT to mouse IgG1 Fab' fragment.
Li J; Wang XH; Wang XM; Chen ZL
Acta Pharmacol Sin; 2006 Feb; 27(2):237-41. PubMed ID: 16412275
[TBL] [Abstract][Full Text] [Related]
7. An expanded genetic code facilitates antibody chemical conjugation involving the lambda light chain.
Kato A; Ohtake K; Tanaka Y; Yokoyama S; Sakamoto K; Shiraishi Y
Biochem Biophys Res Commun; 2021 Mar; 546():35-39. PubMed ID: 33561746
[TBL] [Abstract][Full Text] [Related]
8. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.
Ruddle BT; Fleming R; Wu H; Gao C; Dimasi N
ChemMedChem; 2019 Jun; 14(12):1185-1195. PubMed ID: 30980702
[TBL] [Abstract][Full Text] [Related]
10. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
Humphreys DP; Heywood SP; Henry A; Ait-Lhadj L; Antoniw P; Palframan R; Greenslade KJ; Carrington B; Reeks DG; Bowering LC; West S; Brand HA
Protein Eng Des Sel; 2007 May; 20(5):227-34. PubMed ID: 17452434
[TBL] [Abstract][Full Text] [Related]
11. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
[TBL] [Abstract][Full Text] [Related]
12. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers.
Bhakta S; Raab H; Junutula JR
Methods Mol Biol; 2013; 1045():189-203. PubMed ID: 23913148
[TBL] [Abstract][Full Text] [Related]
13. Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies.
Dickgiesser S; Kellner R; Kolmar H; Rasche N
Methods Mol Biol; 2019; 2033():1-14. PubMed ID: 31332743
[TBL] [Abstract][Full Text] [Related]
14. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
[TBL] [Abstract][Full Text] [Related]
16. Chicken scFvs with an Artificial Cysteine for Site-Directed Conjugation.
Yoon A; Shin JW; Kim S; Kim H; Chung J
PLoS One; 2016; 11(1):e0146907. PubMed ID: 26764487
[TBL] [Abstract][Full Text] [Related]
17. Generation and testing of engineered multimeric Fabs of trastuzumab.
Selis F; Sandomenico A; Cantile M; Sanna R; Calvanese L; Falcigno L; Dell'Omo P; Esperti A; De Falco S; Focà A; Caporale A; Iaccarino E; Truppo E; Scaramuzza S; Tonon G; Ruvo M
Int J Biol Macromol; 2020 Dec; 164():4516-4531. PubMed ID: 32941911
[TBL] [Abstract][Full Text] [Related]
18. Disulfide bond bridged divalent antibody-toxin, (Fab-PE38fl)2, with the toxin PE38 fused to the light chain.
Won J; Choe M
J Microbiol Biotechnol; 2008 Aug; 18(8):1475-81. PubMed ID: 18756111
[TBL] [Abstract][Full Text] [Related]
19. Molecularly defined antibody conjugation through a selenocysteine interface.
Hofer T; Skeffington LR; Chapman CM; Rader C
Biochemistry; 2009 Dec; 48(50):12047-57. PubMed ID: 19894757
[TBL] [Abstract][Full Text] [Related]
20. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
